Cardiovascular Devices
Author：Interventional Cardiology ArchitectDrug Eluting Stents: Cost vs Patency in Value-Based PurchasingDrug eluting stents cost more upfront, but do they deliver better long-term value? Explore patency, reintervention risk, and evidence to make smarter purchasing decisions.May 16, 2026- Author：Interventional Cardiology ArchitectCardiovascular Device Development Bottlenecks Before SubmissionCardiovascular device development often stalls before submission. Explore key bottlenecks in evidence, testing, clinical strategy, and regulatory alignment to reduce delays and improve approval confidence.May 12, 2026
Author：{item.goods_category_9q0k9j8pjx}
{item.title}
{item.description}
{item.add_time}
Weekly Insights
Stay ahead with our curated technology reports delivered every Monday.
Related Industries
- Surgical Consumables Innovation: Which Upgrades Improve OR Efficiency and Clinical Outcomes?Surgical consumables innovation explained: discover which upgrades truly improve OR efficiency, tissue safety, healing outcomes, and value across MIS, interventional care, and wound management.
- Volume Based Procurement: Cost Control Risks and Margin Impact in High-Value ConsumablesVolume based procurement can boost sales yet quietly erode margins in high-value consumables. Learn the hidden cost, compliance, and service risks before the next bid.
- Tissue Regeneration Materials: How to Compare Bioactivity, Degradation, and SafetyTissue regeneration materials compared: learn how to assess bioactivity, degradation, and safety with a practical framework for smarter quality, regulatory, and supplier decisions.